2025.08.05
*Notice* Yamaguchi University-launched venture Noile-Immune Biotech Co., Ltd. aims to establish a research and development collaboration center for PRIME CAR-T cells in partnership with Yamaguchi University ~From Ube City to the world~
On Wednesday, July 23, 2025, Yamaguchi University announced that it would officially launch a project jointly developed with Noile-Immune Biotech Co., Ltd., a venture company founded by Yamaguchi University and led by Professor Koji Tamada, who is affiliated with the Graduate School of Medicine and also serves as the director of the Research Institute for Cell Design and Medical Science. This project aims to achieve the world’s first solid tumor treatment using CAR-T cell therapy and to establish a broad-based collaborative hub. A joint press conference was held at Ube City Hall with the attendance of relevant parties.
This project is being implemented with subsidies from Yamaguchi Prefecture and Ube City. First, Mr. Tokashiki, a director of Noile-Immune Biotech Co., Ltd., explained the project overview, stating that the company aims to establish a research and development collaboration hub for PRIME CAR-T cells using the “PRIME technology,” which is effective against solid tumors, over the next 10 years.
Following this, Mr. Tamada, President and CEO, expressed his aspirations to strengthen and expand collaboration with local communities and businesses through the development of technology applicable to various pharmaceuticals, and to contribute to the treatment of those suffering from cancer by establishing a new pharmaceutical research and development platform centered in Ube City that extends globally.
